Tuesday, 23 September 2014
The 2013 measles epidemic in Wales came as a salutary reminder of the importance of immunisation in preventing communicable diseases. Similarly, it took an outbreak of bird flu in 2010 to act as a wake-up call for people who had become somewhat laissez-faire about protecting themselves against the influenza virus. In this article we look at the dangers of flu, why the immunisation programme is important, and what you can do to reduce the impact of the flu bug on your patients' health and well-being.
Friday, 05 September 2014
A retrospective audit of premature deaths (aged under 75) from cardiovascular disease (CVD) in Leeds showed that patients diagnosed with CVD and placed on disease registers lived on average eight years longer than patients who had not been diagnosed prior to their deaths. If innovations like the NHS Health Check can be used to identify CVD patients in a more equitable manner, there is likely to be a major impact in reducing premature mortality with the potential to reduce health inequalities for disadvantaged groups in the population.
Tuesday, 19 August 2014
In patients with both homozygous and heterozygous familial hypercholesterolaemia (FH), statins with or without ezetimibe are now the mainstay pharmacological therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, combined with lipoprotein apheresis in homozygotes and statin-refractory heterozygotes. These therapies have helped to improve outcomes, but new treatment options areurgently needed, as FH patients continue to be at high risk of premature death due to cardiovascular disease (CVD). HEART UK - The Cholesterol Charity - has provided editorial support and review of this sponsored FH series.This article was made possible by an unrestricted educational grant by Sanofi, who had no control over content.
Friday, 18 July 2014
A meeting report from the British Society for Heart Failure (BSH) 6th Annual Heart Failure day for training and revalidation, held in Glasgow in March 2014.
Friday, 18 July 2014
Most people with coronary heart disease (CHD) can be managed with lifestyle change and optimal medical therapy, but some patients need revascularisation procedures such as angioplasty with stenting (percutaneous coronary intervention [PCI]). These patients spend minimal time in hospital, and GPs have an increasingly important role in follow-up to minimise the risk of adverse events, promote lifestyle change and ensure continuing adherence to medication.
Monday, 07 July 2014
Patient satisfaction with treatment is a key component of the successful management of chronic conditions such as atrial fibrillation (AF). In the EUropean Patient Survey in Atrial Fibrillation (EUPS-AF) survey, UK patients reported the highest rates of satisfaction with their healthcare system and quality of care. However, only about half of UK patients reported receiving regular anticoagulation testing and about one third had never or rarely had a medication review. This survey provides important insights into the current provision of care that should be taken into account when designing and commissioning patient-centred AF services.
Tuesday, 17 June 2014
Acute heart failure–the rapid onset of symptoms and signs secondary to abnormal cardiac function–may occur as new-onset symptoms in a patient without previous known cardiac dysfunction or as acute decompensation of chronic heart failure. Both presentations are often life-threatening and require urgent treatment. Acute heart failure was therefore the ideal focus for the recent annual meeting of the British Society for Heart Failure, which took place in London in November 2013.
Wednesday, 14 May 2014
Homozygous familial hypercholesterolaemia (FH) is a rare disorder with a very high risk of premature cardiac death that must be diagnosed and treated from childhood onwards, usually with lifelong lipoprotein apheresis. Heterozygous FH is much commoner, with a high risk of cardiovascular disease in adults that can be prevented by early diagnosis and statin therapy. HEART UK - The Cholesterol Charity - has provided editorial support and review of this sponsored FH series.This article was made possible by an unrestricted educational grant by Sanofi, who had no control over content.
Friday, 28 February 2014
Remote monitoring is an emerging model of care in heart failure (HF) which has been shown to be clinically beneficial. In this study, patients were recruited to a new telemonitoring programme after referral to a community HF service. Following enrolment, there was a 58% reduction in the risk of HF admissions (0.71 vs. 0.30 per year, p
Monday, 10 February 2014
There have been significant advances in the management of coronary artery disease (CHD) in recent years; including in medical therapy, revascularisation, secondary prevention, cardiac rehabilitation and lifestyle interventions, which have resulted in improved prognosis and life expectancy. As a consequence, an increasing number of patients are living longer with CHD, the commonest clinical presentation of which is angina pectoris. In patients with stable angina, the focus of treatment has therefore shifted towards ensuring optimal symptom control and improving quality of life. Ranolazine is an antianginal approved for patients with stable angina, whose symptoms are inadequately controlled by - or they are intolerant of - first-line therapy.